{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:17:37Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 22.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09555-2d1e-7481-8f2c-92a41dcbc68b\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: methsuximide\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 re", "usd": 0.0, "recall": true }, "codex": { "seconds": 75.4, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09555-2d2a-7183-95da-e13a35f40dc1\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: methsuximide\nRegistry id: vr.tr.methsuximide\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:51:39+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:33+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q906414", "registryId": "vr.tr.methsuximide", "name": "methsuximide", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q906414/", "model": { "registry_id": "vr.tr.methsuximide", "name": "methsuximide", "purpose": "Enable an agent to recognise methsuximide, assess the identity and fitness of a material sample, and determine which handling or pharmaceutical-use decisions its evidence supports.", "definition": "Methsuximide is a synthetic succinimide anticonvulsant whose antiseizure activity is substantially mediated by its active metabolite, N-desmethylmethsuximide, and which is used for absence seizures resistant to other medicines.", "scope_statement": "This model owns the chemical-substance identity registered as vr.tr.methsuximide in PHY / PHY.MAT, its sample-dependent composition and physical state, and its evidence-backed relationships to pharmaceutical products, metabolites and use restrictions.", "in_scope": [ "Molecular identity and authoritative substance identifiers for methsuximide", "Sample grade, assay, impurities and analytical identity evidence", "Physical form, measured properties and storage-dependent condition", "Relationships to methsuximide-containing medicines and metabolic products", "Substance handling hazards and jurisdiction-specific constraints" ], "out_of_scope": [ "Finished capsule formulations, excipients, packaging and product authorisations", "Patient diagnosis, prescribing, dose adjustment and individual treatment outcomes", "Independent models of N-desmethylmethsuximide and other succinimides", "Manufacturing equipment and complete synthesis procedures", "General models of epilepsy and absence seizures" ], "distinguishing_features": [ "Require molecular connectivity consistent with N,2-dimethyl-2-phenylsuccinimide; a succinimide class label alone cannot establish identity. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)", "Check the formula C12H13NO2 and PubChem CID 6476 together with a structure-specific analytical result; formula alone cannot distinguish isomers. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Methsuximide)", "Distinguish the parent compound from N-desmethylmethsuximide when assigning analytical results; the label explicitly distinguishes this metabolite in poisoning assessment. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)", "Treat Celontin as a linked medicine containing methsuximide, rather than identifying the capsule and its excipients as the pure substance. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)" ], "characteristics": [ { "name": "Molecular identity agreement", "kind": "state", "unit_or_values": "confirmed | provisional | conflicting | untested; structure and analytical evidence required", "why_it_matters": "Prevents related succinimides or incorrectly labelled material from being accepted as methsuximide." }, { "name": "Substance identifier mapping", "kind": "relation", "unit_or_values": "Registry id, CAS number, PubChem CID, UNII and EC number where verified, each linked to its authority", "why_it_matters": "Connects records across suppliers and regulatory systems without silently merging different chemical entities." }, { "name": "Methsuximide assay", "kind": "measurement", "unit_or_values": "% mass fraction, with as-is or dry basis, method and uncertainty", "why_it_matters": "Establishes actual parent-compound content rather than relying on nominal purity." }, { "name": "Related substances and residuals", "kind": "measurement", "unit_or_values": "% or mg/kg by named analyte; method, detection limit and acceptance specification", "why_it_matters": "Separates methsuximide from synthesis residuals, degradation products and other detected compounds." }, { "name": "Material grade", "kind": "category", "unit_or_values": "reference standard | research reagent | pharmaceutical ingredient | unspecified; supporting specification", "why_it_matters": "Chemical identity alone does not establish suitability for pharmaceutical manufacture." }, { "name": "Physical form and thermal behaviour", "kind": "measurement", "unit_or_values": "Observed phase; melting interval in °C; thermal method, pressure and decomposition observation", "why_it_matters": "Supports comparison with qualified reference material and detection of altered or contaminated samples." }, { "name": "Solubility under stated conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L, with solvent, temperature, pH where relevant and equilibration method", "why_it_matters": "Supports analytical preparation and formulation evaluation without assuming solubility transfers between media." }, { "name": "Sample disposition", "kind": "state", "unit_or_values": "quarantined | released for specified use | retest required | rejected", "why_it_matters": "Makes permitted next actions depend on identity, quality and storage evidence." }, { "name": "Parent-metabolite relationship", "kind": "relation", "unit_or_values": "Named metabolite, transformation evidence and analyte-specific biological measurements", "why_it_matters": "Prevents parent-compound measurements from being substituted for metabolite measurements." }, { "name": "Applicable hazard and regulatory record", "kind": "relation", "unit_or_values": "Dated SDS, GHS assessment, exposure-limit authority and jurisdiction-specific ingredient or product record", "why_it_matters": "Keeps bulk-material handling requirements distinct from restrictions attached to a medicine." } ], "affordances": [ "Reconcile a supplier-labelled methsuximide sample with authoritative identity records and reference analyses.", "Compare assay and impurity results with the specification required for a proposed use.", "Select documented analytical preparation and storage conditions appropriate to the material form.", "Link a medicine to its methsuximide ingredient while preserving product-specific strength and excipients.", "Separate parent and metabolite evidence when reviewing biological analyses.", "Release, quarantine or request retesting of a sample using explicit evidence and decision authority." ], "agent_conduct": { "may": [ "Describe methsuximide, its use in absence seizures and its warnings from official drug information.", "Remind patients to keep taking anticonvulsants as prescribed and to talk to their doctor before changes.", "Track stock and expiry in a pharmacy the agent is authorized to manage." ], "must_not": [ "Recommend, dose or adjust methsuximide for a particular patient.", "Advise stopping an anticonvulsant suddenly.", "Downplay warnings on mood changes, blood disorders or pregnancy.", "Help anyone obtain it without a prescription." ], "requires_human": [ "Any decision to start, stop or change an antiseizure medicine." ] }, "ethics": { "considerations": [ "Stopping antiseizure medicines abruptly can trigger dangerous seizures.", "People with epilepsy face stigma and need accurate, respectful information." ], "affected_parties": [ "People with epilepsy", "Families and carers", "Prescribers" ] }, "owners": { "steward": "The prescribing clinician answers for each use; medicines regulators authorize the product.", "master_systems": [ "National medicines registers" ] }, "failure_modes_and_hazards": [ "Can cause drowsiness, blood disorders and changes in mood or behaviour.", "Sudden withdrawal can provoke seizures." ], "what_it_is_for": [ "Methsuximide is encountered as a pharmaceutical active substance and in prescription medicines for absence seizures resistant to other medicines.", "It is also encountered in pharmaceutical quality testing and studies of its active metabolite." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification issued by the WHO Collaborating Centre for Drug Statistics Methodology assigns methsuximide, listed as mesuximide, code N03AD03.", "The Federal Food, Drug, and Cosmetic Act, enacted by the United States Congress and administered by the Food and Drug Administration, governs its medicinal products in the United States." ], "visual_identification": [ "A material label naming methsuximide or mesuximide provides a documentary identification cue that requires supporting analytical evidence.", "The molecular formula C12H13NO2 on an accompanying label or certificate helps distinguish the stated substance from other succinimide anticonvulsants.", "The pure substance is described as a white crystalline powder, an appearance shared by many compounds and insufficient to confirm identity." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q906414: methsuximide", "url": "https://www.wikidata.org/wiki/Q906414", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Mesuximide", "url": "https://en.wikipedia.org/wiki/Mesuximide", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "methsuximide-identity", "name": "Methsuximide identity", "description": "Establishes which chemical entity the registry entry denotes.", "rationale": "A medicine name, succinimide class assignment or approximate spelling cannot independently authenticate methsuximide.", "layers": [ { "id": "molecular-boundary", "name": "Molecular boundary", "description": "Defines the parent structure and separates neighbouring chemical entities.", "findings": [ { "id": "parent-structure-match", "name": "Parent structure match", "description": "Record structural identity evidence and the reference against which the candidate material was compared.", "questions": [ { "text": "Which authoritative structure defines methsuximide, including any specified stereochemical composition?", "kind": "definition", "id": "parent-structure-match-q01" }, { "text": "Which analytical observations distinguish this sample from other succinimides and the N-desmethyl derivative?", "kind": "measurement", "id": "parent-structure-match-q02" } ] } ] }, { "id": "identifier-reconciliation", "name": "Identifier reconciliation", "description": "Connects the registered substance to external chemical records without importing product identity.", "findings": [ { "id": "authority-linked-identifiers", "name": "Authority-linked identifiers", "description": "Maintain verified identifiers and candidate synonyms with their source and identity scope.", "questions": [ { "text": "Which CAS, PubChem, UNII and applicable EC records resolve to the same methsuximide structure?", "kind": "provenance", "id": "authority-linked-identifiers-q01" }, { "text": "Does each encountered name denote methsuximide itself, a containing medicine or a different chemical entity?", "kind": "boundary", "id": "authority-linked-identifiers-q02" } ] } ] } ] }, { "id": "methsuximide-material-quality", "name": "Methsuximide material quality", "description": "Describes the composition and qualification of a particular methsuximide lot.", "rationale": "A correctly identified substance can still have insufficient purity or documentation for its proposed use.", "layers": [ { "id": "assay-and-related-substances", "name": "Assay and related substances", "description": "Separates parent content from impurities and other sample components.", "findings": [ { "id": "selective-composition-evidence", "name": "Selective composition evidence", "description": "Require methods that quantify methsuximide with demonstrated selectivity for relevant accompanying compounds.", "questions": [ { "text": "What is the methsuximide mass fraction, on what reporting basis, and with what measurement uncertainty?", "kind": "measurement", "id": "selective-composition-evidence-q01" }, { "text": "Which related substances, residual solvents and water measurements are required by the applicable specification?", "kind": "definition", "id": "selective-composition-evidence-q02" }, { "text": "Can the assay resolve methsuximide from the impurities actually encountered in this lot?", "kind": "measurement", "id": "selective-composition-evidence-q03" } ] } ] }, { "id": "grade-and-lot-disposition", "name": "Grade and lot disposition", "description": "Connects lot evidence to a qualified material use.", "findings": [ { "id": "supported-grade-claim", "name": "Supported grade claim", "description": "Treat grade and release status as documented conclusions rather than consequences of a supplier's substance name.", "questions": [ { "text": "Which dated specification and certificate support this lot's claimed methsuximide grade?", "kind": "provenance", "id": "supported-grade-claim-q01" }, { "text": "Does the evidence permit the proposed analytical or manufacturing use, or require quarantine or retesting?", "kind": "action", "id": "supported-grade-claim-q02" } ] } ] } ] }, { "id": "methsuximide-physical-condition", "name": "Methsuximide physical condition", "description": "Records condition-dependent properties and changes during storage or preparation.", "rationale": "Physical-property values and product storage instructions cannot be applied indiscriminately to every bulk sample.", "layers": [ { "id": "phase-and-preparation-properties", "name": "Phase and preparation properties", "description": "Qualifies thermal and solubility observations with their experimental conditions.", "findings": [ { "id": "qualified-property-measurements", "name": "Qualified property measurements", "description": "Record measured methsuximide properties with sample composition, methods and conditions.", "questions": [ { "text": "What phase and melting interval does the qualified methsuximide sample exhibit, and is decomposition observed?", "kind": "measurement", "id": "qualified-property-measurements-q01" }, { "text": "What solubility is demonstrated in the intended preparation medium at the stated temperature and pH?", "kind": "measurement", "id": "qualified-property-measurements-q02" }, { "text": "Is any reported boiling point experimental, estimated or invalidated by decomposition?", "kind": "provenance", "id": "qualified-property-measurements-q03" } ] } ] }, { "id": "storage-and-change", "name": "Storage and change", "description": "Tracks whether handling history compromises the lot's qualified condition.", "findings": [ { "id": "stability-supported-disposition", "name": "Stability-supported disposition", "description": "Base storage limits and retest decisions on evidence applicable to the actual methsuximide material and container.", "questions": [ { "text": "Which stability data support temperature, moisture and light controls for this bulk material or prepared solution?", "kind": "provenance", "id": "stability-supported-disposition-q01" }, { "text": "After an excursion, which methsuximide assay or degradation measurements determine whether the material remains usable?", "kind": "action", "id": "stability-supported-disposition-q02" } ] } ] } ] }, { "id": "methsuximide-pharmaceutical-relations", "name": "Methsuximide pharmaceutical relations", "description": "Connects the substance to medicines and biological transformation while retaining separate entity boundaries.", "rationale": "The ingredient, finished medicine and measured metabolite support different decisions.", "layers": [ { "id": "ingredient-to-medicine", "name": "Ingredient to medicine", "description": "Locates therapeutic claims on the appropriate medicine and jurisdiction.", "findings": [ { "id": "label-scoped-use", "name": "Label-scoped use", "description": "The cited US Celontin label identifies use for absence seizures refractory to other drugs; represent this as a product-label relationship. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)", "questions": [ { "text": "Which dated medicine label supports the indication associated with this methsuximide-containing product?", "kind": "provenance", "id": "label-scoped-use-q01" }, { "text": "Which strength, formulation and use restrictions belong to the linked medicine rather than to bulk methsuximide?", "kind": "boundary", "id": "label-scoped-use-q02" } ] } ] }, { "id": "parent-and-metabolite-evidence", "name": "Parent and metabolite evidence", "description": "Separates administered chemical identity from analytes observed after administration.", "findings": [ { "id": "analyte-specific-interpretation", "name": "Analyte-specific interpretation", "description": "Attach biological measurements to their exact parent or metabolite analyte, matrix and sampling context.", "questions": [ { "text": "Does the result quantify methsuximide, N-desmethylmethsuximide or a combined analytical signal?", "kind": "definition", "id": "analyte-specific-interpretation-q01" }, { "text": "What matrix, sampling time, units and assay selectivity qualify the result?", "kind": "measurement", "id": "analyte-specific-interpretation-q02" }, { "text": "Which primary evidence establishes the metabolite's activity and persistence relative to methsuximide?", "kind": "provenance", "id": "analyte-specific-interpretation-q03" } ] } ] } ] }, { "id": "methsuximide-hazards-and-permissions", "name": "Methsuximide hazards and permissions", "description": "Supports evidence-based handling and distinguishes substance constraints from medicine regulation.", "rationale": "Therapeutic use does not establish bulk handling safety, and medicine approval does not qualify an arbitrary chemical lot.", "layers": [ { "id": "bulk-handling-evidence", "name": "Bulk handling evidence", "description": "Establishes controls for the actual methsuximide material and operation.", "findings": [ { "id": "material-specific-exposure-controls", "name": "Material-specific exposure controls", "description": "Use applicable hazard records and exposure assessments for weighing, transfer, spills and disposal.", "questions": [ { "text": "Which dated SDS and jurisdictional GHS assessment apply to this methsuximide grade and physical form?", "kind": "provenance", "id": "material-specific-exposure-controls-q01" }, { "text": "Is there an authoritative occupational exposure limit, or only a supplier or internal control limit?", "kind": "definition", "id": "material-specific-exposure-controls-q02" }, { "text": "Which documented controls govern this quantity and operation, including spill collection and disposal?", "kind": "action", "id": "material-specific-exposure-controls-q03" } ] } ] }, { "id": "clinical-and-regulatory-boundaries", "name": "Clinical and regulatory boundaries", "description": "Links restrictions to their source, subject and jurisdiction.", "findings": [ { "id": "restriction-scope", "name": "Restriction scope", "description": "The cited label contraindicates use in patients with succinimide hypersensitivity; retain this as a clinical restriction separate from workplace classification. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)", "questions": [ { "text": "Which clinical warnings and interaction records should an agent retrieve before passing methsuximide information into a treatment workflow?", "kind": "action", "id": "restriction-scope-q01" }, { "text": "Does a cited restriction govern the chemical substance, a pharmaceutical ingredient lot or a particular marketed medicine?", "kind": "boundary", "id": "restriction-scope-q02" }, { "text": "Which authority and effective date support the applicable supply or use restriction?", "kind": "provenance", "id": "restriction-scope-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall-based information; no sources were consulted.", "Current indications, availability, product specifications and regulatory requirements should be verified for the relevant jurisdiction.", "Solid-state properties, stereochemical composition, purity specifications and occupational hazard classifications require source verification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "77-41-8", "note": "Identifies methsuximide as a chemical substance." }, { "scheme": "Molecular formula", "value_or_pattern": "C12H13NO2", "note": "Describes elemental composition rather than uniquely identifying the structure." }, { "scheme": "International Nonproprietary Name", "value_or_pattern": "mesuximide", "note": "International name for the substance commonly called methsuximide in the United States." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active pharmaceutical ingredient in oral anticonvulsant medicines.", "Treatment of absence seizures that have not responded adequately to other anticonvulsants." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "203.24", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Drowsiness, dizziness and impaired coordination can affect activities requiring alertness.", "Gastrointestinal adverse effects can include nausea, vomiting and abdominal discomfort.", "Rare but serious blood dyscrasias, including potentially fatal reductions in blood-cell production, have been reported.", "Severe hypersensitivity and serious skin reactions can occur.", "Accumulation of the active metabolite and interactions with other anticonvulsants can contribute to toxicity." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "The names methsuximide and mesuximide refer to the same substance; naming conventions differ between the United States and international usage." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Ethosuximide", "difference": "A distinct succinimide anticonvulsant with an ethyl substituent instead of methsuximide's phenyl substituent and without its N-methyl group." }, { "name": "Phensuximide", "difference": "A related succinimide anticonvulsant that lacks methsuximide's methyl substituent at ring position 3." }, { "name": "N-desmethylmethsuximide", "difference": "The active metabolite formed by removal of the parent's N-methyl group; it is a separate chemical substance." }, { "name": "Methsuximide capsules", "difference": "A formulated medicinal product containing methsuximide and excipients, rather than the pure chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of methsuximide this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative records establish the CAS number, applicable EC identifier, accepted synonyms and stereochemical scope of this registry entry?", "Which current compendial or validated specifications define methsuximide assay, related-substance limits and pharmaceutical ingredient qualification?", "What experimentally supported melting, solubility, thermal decomposition and storage-stability data apply to identified bulk forms and prepared solutions?", "Which jurisdiction-specific GHS classifications and occupational exposure limits, if any, are supported for bulk methsuximide?", "Which primary studies establish parent-versus-metabolite activity, persistence and analytical interpretation, and where does that evidence remain uncertain?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 32 } }